Truly Labs AB was founded in early 2015 by former AstraZeneca employees with altogether more than 100 years experience from the Life Science sector, with an emphasis on bringing projects from in vitro studies and animal models into concept testing in patients.
Our experiences span from pre-clinical research to early clinical drug discovery, pharmaceutical and biotech companies as well as both small molecules and biologicals. We have experience from project management, international environment and cross-functional teams.
Our main expertise is in translational science and inflammatory diseases, and we have experiences from several therapeutic areas, including Respiratory, Oncology, Cardiovascular, Gastrointestinal and Autoimmunity.
Karin has a strong scientific expertise in Pharmaceutical development of large and small molecules. She obtained her Ph. D from Dept. of Immunotechnology at Lund University. Karin has over 20 years experience from the pharmaceutical industry (BioInvent, Ixsys Inc. PharmaciaUpjohn, Active Biotech and AstraZeneca) developing drugs for cancer and Respiratory/Inflammation. At AstraZeneca R&D Lund Karin was instrumental in the implementation of translational science and biomarker strategies within the discovery projects, and worked closely with the early clinical organization. She has complemented her scientific training and experience with a degree in marketing and leadership. Since 2011 she is the CEO and co-founder of Truly Translational Sweden AB and holds the same position in Truly Labs AB since 2015.
Charlott has a strong scientific expertise within in vivo pharmacology and pharmaceutical development of small molecules as well as biologics. She has a Ph. D. in Medical Sciences from Lund University whereafter she worked for two years as a visiting scientist at Harvard Medical School in Boston. Charlott has a long experience from the pharmaceutical industry working in both large pharma and small Biotech companies (Pharmacia Upjohn, Active Biotech, Cartela and AstraZeneca). During these years Charlott’s work has been focused on inflammation, autoimmunity and respiratory diseases. In this work translational science i.e. linking effect to exposure and pre-clinical readouts to man has been a key focus. Since 2011 she is the CSO and co-founder of Truly Translational Sweden AB and holds the same position in Truly Labs AB since 2015.
Per-Ola has over twenty years of experience of drug discovery with the main focus on in vivo pharmacology. The main disease areas have been respiratory diseases and rheumatoid arthritis. At Astra Zeneca R&D Lund Per-Ola lead the set up and co-ordination of major global collaborations with world leading academic groups in the area of COPD. In addition, Per-Ola has several years of experience from line management and senior scientific roles within discovery organizations before he took on a role in the clinical organization where the lead clinical trials. In 2012 Per-Ola joined Truly Translational as Principal Scientist. Since 2015 Per-Ola holds a position as Head of In Vivo Biology at Truly Labs AB.
Eskil has several years of experience of pharmaceutical development of small molecules and biologics. He has a strong scientific background with a PhD in Medical microbiology from Lund University followed by post doc sessions at University of Cambridge and Lund University working within immunology and vaccine development, respectively. He has worked at small as well as large pharma organizations (ACADIA Pharmaceuticals and AstraZeneca). Eskil has particular interest and expertise in pharmacokinetics (PK) and has worked as DMPK project leader at AstraZeneca. In that role, he represented the DMPK organization in drug projects from lead optimization up to Ph2b, a role in the boundary between the discovery and the clinical organization. The role encompassed accountability for the delivery of the ADME, PK and PK/PD parts for candidate selection. Over the years, Eskil has gained experience from working with respiratory disease in e.g. asthma, COPD, and cystic fibrosis, but also autoimmune indications. Eskil joined Truly Labs in 2017 as Principal Scientist and Consultant and will strengthen the capability in preclinical and clinical pharmacokinetics as well as in quantitative pharmacology (PK/PD) and ADME.
Hanna has more than 15 years of experience of drug discovery with the main focus on in vivo pharmacology. The main focus has been inflammatory disease including work with both pharmacodynamics and disease mechanism models with the aim of characterizing and developing pharmaceutical drugs. Hanna has from her work at AstraZeneca R&D an expertise in respiratory diseases with emphasis on different techniques for measuring lung function alterations in rodents. At AstraZeneca R&D Hanna lead the work to include lung function as a read-out in both new and existing rodent models of asthma and COPD. The last couple of years Hanna has been working in the in vitro diagnostic industry, at HemoCue AB, as a test leader within design verification and validation of new products. Hanna joined Truly Labs as Senior Scientist in 2015.
Janne has more than 15 years of experience within the field of inhalation. Janne was pivotal in the set up of the inhalation systems used within safety assessment at AstraZeneca in Södertälje and later on in the move of the AZ Respiratory IMED to Mölndal. At AstraZeneca Lund Janne was key in the set up of a state of the art inhalation system supporting all pre-clinical inhalation projects, covering both nebulized and dry powder formulations. Janne joined Truly Labs in 2015.
Camilla has a strong background in biochemistry and life science research. She obtained her Ph. D. from Dept. of Immunology at Lund University in 2015 and also has a MSc in chemistry. Over the years she has developed strong skills in a wide range of biochemical techniques and molecular and cellular biology. Lately Camilla has been working with vaccine development at Lund University in collaboration with Minervax where she was responsible for analysis of human serums from clinical trials. Camilla joined Truly Labs in 2016/09/01
Jian has more than 20 years’ experience in the life science sector. She obtained her PhD in molecular biology and cell biology from Microbiology and Tumor Biology Center (MTC) at Karolinska Institute in 2003, followed by postdoc positions in Denmark and Sweden. Before she joined Truly Labs, she worked in the department of Clinical Genetics at Lund University where she developed both in vitro and in vivo methods to investigate genetic mechanisms of pediatric leukemia. By utilizing CRISPR/Cas9 she generated leukemia mouse models to identify epigenetic alterations that occur in pediatric leukemia. During the more than 20 years that Jian has worked with life science research, she has acquired extensive knowledge and broad experience of performing both in vitro and in vivo studies. Jian joined Truly Labs in 2017.
Emma has more than 15 years of experience of drug discovery and life science research. Following a MSc in Biology and a one year scholarship at Lund University Biomedical Research School she joined AstraZeneca in 2001 where she focused on validation of cell-based assays, with primary cells and cell lines, to be used in drug screening. She also build a strong expertise in areas of flow cytometry and high content screening, taking on the role as Flow cytometry core facility manager. In 2011, Emma took on a position as Lab Manager for a research group at Lund University where she gained further experience in a wide range of molecular and cellular techniques and in areas such as purchasing, event coordination and safety work. Emma joined Truly Labs late 2016